Roivant Sciences Ltd. (ROIV) Presents at Bernstein 2nd Annual Global Healthcare Conference Transcript

Company Overview - Roivant is a biopharma company focused on development-stage and clinical-stage drug development [1] - The company has a market capitalization of approximately $10 billion and holds about $4.5 billion in cash following a drug sale to Roche [1] - Roivant has several late-stage clinical programs, with one currently in the registration process with the FDA after positive data [1] Subsidiary Information - Roivant has a public subsidiary named Immunovant, which focuses on an anti-FcRn antibody [1] - The market value of Roivant's stake in Immunovant is approximately $2 billion [1]